2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. 2015 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations focusing on clinical management http://ow.ly/RiDLb

[1]  M. Humbert,et al.  Pulmonary veno-occlusive disease , 2016, European Respiratory Journal.

[2]  Dave P. Miller,et al.  Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)". , 2016, Circulation.

[3]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[4]  H. Ghofrani,et al.  Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension , 2015, European Respiratory Journal.

[5]  M. B. Bacchi Reggiani,et al.  Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights , 2015, European Respiratory Journal.

[6]  M. Humbert,et al.  Criteria for diagnosis of exercise pulmonary hypertension , 2015, European Respiratory Journal.

[7]  G. Simonneau,et al.  Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study , 2015 .

[8]  M. Humbert,et al.  Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  E. Grünig,et al.  PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension , 2015, European Respiratory Journal.

[10]  A. Hanlon,et al.  Development and initial psychometric properties of the Pulmonary Arterial Hypertension Symptom Scale (PAHSS). , 2015, Applied nursing research : ANR.

[11]  M. Humbert,et al.  Pulmonary arterial hypertension in patients treated with interferon , 2014, European Respiratory Journal.

[12]  G. Lewis,et al.  Characterization of pulmonary hypertension in heart failure using the diastolic pressure gradient: limitations of a solitary measurement. , 2015, JACC. Heart failure.

[13]  Thomas P Cappola,et al.  The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. , 2015, JACC. Heart failure.

[14]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[15]  A. Swift,et al.  CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry , 2014, Thorax.

[16]  Fuqiang Wen,et al.  CT-Base Pulmonary Artery Measurementin the Detection of Pulmonary Hypertension , 2014, Medicine.

[17]  M. Humbert,et al.  Update in systemic sclerosis-associated pulmonary arterial hypertension. , 2014, Presse medicale.

[18]  M. Humbert,et al.  Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. , 2014, Presse medicale.

[19]  R. Ciconelli,et al.  Quality of life as a prognostic marker in pulmonary arterial hypertension , 2014, Health and Quality of Life Outcomes.

[20]  M. Humbert,et al.  Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature , 2014, European Respiratory Journal.

[21]  R. Naeije,et al.  Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. , 2014, American journal of respiratory and critical care medicine.

[22]  S. Rosenkranz,et al.  Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. , 2014, International journal of cardiology.

[23]  H. Hillege,et al.  Identification of treatment goals in paediatric pulmonary arterial hypertension , 2014, European Respiratory Journal.

[24]  J. Grapsa,et al.  Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension. , 2014, Journal of the American College of Cardiology.

[25]  M. Revel,et al.  Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism , 2014, Thrombosis and Haemostasis.

[26]  Z. Jing,et al.  Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients , 2014, European Respiratory Journal.

[27]  S. Ghio,et al.  Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. , 2014, Chest.

[28]  T. Fukuda,et al.  Organized thrombus in pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension; imaging with cone beam computed tomography , 2014, Japanese Journal of Radiology.

[29]  B. Lipworth,et al.  Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[30]  R. Barst,et al.  STARTS-2: Long-Term Survival With Oral Sildenafil Monotherapy in Treatment-Naive Pediatric Pulmonary Arterial Hypertension , 2014, Circulation.

[31]  Angelo Branzi,et al.  Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. , 2014, European heart journal.

[32]  M. Humbert,et al.  Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study , 2014, European Respiratory Journal.

[33]  T. Fukuda,et al.  Right ventricular reverse remodelling after balloon pulmonary angioplasty , 2014, European Respiratory Journal.

[34]  D. Carroll,et al.  Health-Related Quality of Life and Psychological States in Patients With Pulmonary Arterial Hypertension , 2014, The Journal of cardiovascular nursing.

[35]  D. Kass,et al.  Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[36]  J. Granton,et al.  EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. , 2014, American heart journal.

[37]  W. Chung,et al.  EIF2AK4 mutations in pulmonary capillary hemangiomatosis. , 2014, Chest.

[38]  J. Wharton,et al.  Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. , 2014, Rheumatology.

[39]  R. Speich,et al.  Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) , 2013, Circulation.

[40]  H. Hillege,et al.  Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre , 2014, Heart.

[41]  D. Brodie,et al.  Extracorporeal Membrane Oxygenation as a Novel Bridging Strategy for Acute Right Heart Failure in Group 1 Pulmonary Arterial Hypertension , 2014, ASAIO journal.

[42]  J. Marcus,et al.  Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension–Targeted Therapy: The EURO-MR Study , 2014, Circulation. Cardiovascular imaging.

[43]  J. Wild,et al.  Prognostic Value of Cardiovascular Magnetic Resonance Imaging Measurements Corrected for Age and Sex in Idiopathic Pulmonary Arterial Hypertension , 2014, Circulation. Cardiovascular imaging.

[44]  J. Newman,et al.  High Prevalence of Occult Pulmonary Venous Hypertension Revealed by Fluid Challenge in Pulmonary Hypertension , 2014, Circulation. Heart failure.

[45]  H. Heinzl,et al.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study , 2013, Annals of the rheumatic diseases.

[46]  M. Humbert,et al.  EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension , 2013, Nature Genetics.

[47]  J. Wilkinson,et al.  Beta-adrenergic adaptation in idiopathic dilated cardiomyopathy: differences between children and adults. , 2014, European heart journal.

[48]  S. Solomon,et al.  GUIDELINES AND STANDARDS , 2010 .

[49]  Toru Satoh,et al.  Definitions and diagnosis of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[50]  W. Seeger,et al.  Algorithm of Pulmonary Arterial Hypertension , 2022 .

[51]  F. Martinez,et al.  Pulmonary hypertension due to left heart diseases. , 2013, Journal of the American College of Cardiology.

[52]  F. Martinez,et al.  Pulmonary hypertension in chronic lung diseases. , 2013, Journal of the American College of Cardiology.

[53]  G. Simonneau,et al.  The Fifth World Symposium on Pulmonary Hypertension. , 2013, Journal of the American College of Cardiology.

[54]  T. Fleming,et al.  Pediatric pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[55]  O. Sitbon,et al.  Treatment goals of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[56]  P. Ferrari,et al.  Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives , 2013, European Respiratory Review.

[57]  A. Peacock,et al.  Cardiac magnetic resonance imaging in pulmonary arterial hypertension , 2013, European Respiratory Review.

[58]  T. Lahm,et al.  World Health Organization group 5 pulmonary hypertension. , 2013, Clinics in chest medicine.

[59]  M. Humbert,et al.  Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. , 2013, Arthritis and rheumatism.

[60]  P. Corris,et al.  emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension , 2013, European Respiratory Journal.

[61]  I. Susanto,et al.  Transition from Hepatopulmonary Syndrome to Portopulmonary Hypertension: A Case Series of 3 Patients , 2013, Case reports in pulmonology.

[62]  C. Fischer,et al.  Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension , 2013, Circulation.

[63]  A. Morton,et al.  Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. , 2013, JACC. Cardiovascular imaging.

[64]  G. Coghlan Does left heart disease cause most systemic sclerosis associated pulmonary hypertension? , 2013, European Respiratory Journal.

[65]  R. Speich,et al.  Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. , 2013, International journal of cardiology.

[66]  W. Klepetko,et al.  Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy , 2013, Thorax.

[67]  A. Manes,et al.  New treatment strategies for pulmonary arterial hypertension: hopes or hypes? , 2013, Journal of the American College of Cardiology.

[68]  G. Stone,et al.  Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). , 2013, Journal of the American College of Cardiology.

[69]  G. Hansmann,et al.  Registries for paediatric pulmonary hypertension , 2013, European Respiratory Journal.

[70]  M. Hoeper,et al.  Atrial flutter and fibrillation in patients with pulmonary hypertension. , 2013, International journal of cardiology.

[71]  E. Wang,et al.  Role of Pretransplant Echocardiographic Evaluation in Predicting Outcomes Following Liver Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[72]  P. Pellikka,et al.  Outcome Prediction by Quantitative Right Ventricular Function Assessment in 575 Subjects Evaluated for Pulmonary Hypertension , 2013, Circulation. Cardiovascular imaging.

[73]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[74]  R. Hetzer,et al.  Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. , 2013, International journal of cardiology.

[75]  N. Westerhof,et al.  Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses , 2013, European Respiratory Journal.

[76]  Amit R. Patel,et al.  QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. , 2013, International journal of cardiology.

[77]  B. Borlaug,et al.  Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. , 2013, JACC. Heart failure.

[78]  H. Ghofrani,et al.  Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction: A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study , 2013, Circulation.

[79]  W. Chung,et al.  A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[80]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[81]  Chen Wang,et al.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.

[82]  A. Ragnarsson,et al.  Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension , 2013, Heart.

[83]  K. Fukuda,et al.  Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. , 2013, JACC. Cardiovascular interventions.

[84]  N. Rothfield,et al.  Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients , 2013, The clinical respiratory journal.

[85]  R. Barst,et al.  Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. , 2013, Chest.

[86]  M. Arzt,et al.  Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension , 2013, European journal of heart failure.

[87]  G. Karatasakis,et al.  Complications Leading to Sudden Cardiac Death in Pulmonary Arterial Hypertension , 2013, Respiratory Care.

[88]  A. Torbicki,et al.  Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension , 2013, Thrombosis and Haemostasis.

[89]  L. Pacheco,et al.  Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. , 2013, Chest.

[90]  L. Chan,et al.  Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. , 2013, Respiratory medicine.

[91]  J. Feinstein,et al.  Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice , 2013, European Respiratory Journal.

[92]  J. Lock,et al.  Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[93]  R. Naeije,et al.  Chronic thromboembolic pulmonary hypertension: role of medical therapy , 2013, European Respiratory Journal.

[94]  C. Denton,et al.  Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. , 2013, Arthritis and rheumatism.

[95]  A. Geerts,et al.  Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation , 2013, European journal of gastroenterology & hepatology.

[96]  Y. Boudjemline,et al.  Patent Ductus Arteriosus Stenting (Transcatheter Potts Shunt) for Palliation of Suprasystemic Pulmonary Arterial Hypertension: A Case Series , 2013, Circulation. Cardiovascular interventions.

[97]  W. Fang,et al.  [A comparison of ventilation/perfusion single photon emission CT and CT pulmonary angiography for diagnosis of pulmonary embolism]. , 2013, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[98]  Yuhui Zhang,et al.  Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. , 2013, Chest.

[99]  J. Barberà,et al.  Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial , 2013, European Respiratory Journal.

[100]  Z. Jing,et al.  Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial , 2013, Circulation.

[101]  L. Chan,et al.  Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. , 2013, Chest.

[102]  H. Olschewski,et al.  Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. , 2013, Chest.

[103]  H. Marshall,et al.  3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry , 2013, Thorax.

[104]  M. Humbert,et al.  Chronic thromboembolic pulmonary hypertension: advances from bench to patient management , 2013, European Respiratory Journal.

[105]  B. Levine,et al.  Hemodynamic Responses to Rapid Saline Loading: The Impact of Age, Sex, and Heart Failure , 2013, Circulation.

[106]  R. Barst,et al.  Clinical trials in neonates and children: Report of the pulmonary hypertension academic research consortium pediatric advisory committee , 2013, Pulmonary circulation.

[107]  M. Humbert,et al.  Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era , 2012, Annals of the rheumatic diseases.

[108]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[109]  Vittorio Pengo,et al.  Chronic thromboembolic pulmonary hypertension. , 2006, Journal of the American College of Cardiology.

[110]  M. Humbert,et al.  High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. , 2013, Chest.

[111]  M. Humbert,et al.  Pulmonary arterial hypertension: epidemiology and registries. , 2013, Journal of the American College of Cardiology.

[112]  Dave P. Miller,et al.  Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. , 2013, Chest.

[113]  M. Hudson,et al.  High prevalence of occult left heart disease in scleroderma-pulmonary hypertension , 2012, European Respiratory Journal.

[114]  J. Newman,et al.  Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[115]  J. Vachiéry,et al.  Challenges in the diagnosis and treatment of pulmonary arterial hypertension , 2012, European Respiratory Review.

[116]  A. Torbicki,et al.  Pulmonary artery dilatation correlates with the risk of unexpected death in chronic arterial or thromboembolic pulmonary hypertension. , 2012, Chest.

[117]  E. Castañer,et al.  Imaging findings in pulmonary vasculitis. , 2012, Seminars in ultrasound, CT, and MR.

[118]  D. Badesch,et al.  Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. , 2012, Chest.

[119]  M. Ando,et al.  Percutaneous Transluminal Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension , 2012, Circulation. Cardiovascular interventions.

[120]  A. Ogawa,et al.  Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension , 2012, Circulation. Cardiovascular interventions.

[121]  T. Fleming,et al.  Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.

[122]  M. Humbert,et al.  Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey , 2012, European Respiratory Journal.

[123]  R. Naeije,et al.  Echocardiography of pulmonary vascular function in asymptomatic carriers of BMPR2 mutations , 2012, European Respiratory Journal.

[124]  M. Humbert,et al.  Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. , 2012, Chest.

[125]  S. Rich,et al.  Noninvasive cardiac output measurements in patients with pulmonary hypertension , 2012, European Respiratory Journal.

[126]  Jeff A Sloan,et al.  Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[127]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[128]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease (version 2012). , 2012, European heart journal.

[129]  J. Wild,et al.  Pulmonary hypertension in COPD: results from the ASPIRE registry , 2012, European Respiratory Journal.

[130]  P. Gargiulo,et al.  Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. , 2012, Journal of the American College of Cardiology.

[131]  R. Speich,et al.  The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) , 2012, Health and Quality of Life Outcomes.

[132]  M. Humbert,et al.  Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. , 2012, Arthritis and rheumatism.

[133]  R. Benza,et al.  World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[134]  T. Welte,et al.  Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. , 2012, American journal of respiratory and critical care medicine.

[135]  R. Naeije,et al.  The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease , 2012, European Respiratory Journal.

[136]  M. Guazzi,et al.  Pulmonary Hypertension Due to Left Heart Disease , 2012, Circulation.

[137]  M. Madani,et al.  Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. , 2012, The Annals of thoracic surgery.

[138]  T. De Marco,et al.  Pulmonary hypertension associated with left-sided heart disease. , 2012, Heart failure clinics.

[139]  E. Milne Forgotten gold in diagnosing pulmonary hypertension: the plain chest radiograph. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[140]  Jim M Wild,et al.  Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry , 2012, Journal of Cardiovascular Magnetic Resonance.

[141]  C. Fischer,et al.  Exercise training in pulmonary arterial hypertension associated with connective tissue diseases , 2012, Arthritis Research & Therapy.

[142]  J. Yuan,et al.  Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding , 2012, European Respiratory Journal.

[143]  A. Munnich,et al.  Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation , 2012, European Respiratory Journal.

[144]  M. Humbert,et al.  Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension , 2012, European Respiratory Journal.

[145]  M. Bartels,et al.  Sildenafil for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial , 2012, COPD.

[146]  W. Fang,et al.  Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography , 2012, Nuclear medicine communications.

[147]  M. Humbert,et al.  Résultats tardifs de la commissurotomie mitrale percutanée à 20 ans Création et validation d ’ un score de risque prédisant les résultats fonctionnels à long terme à partir d ’ une série de 912 patients , 2012 .

[148]  H. Palevsky,et al.  Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.

[149]  M. Humbert,et al.  Pulmonary hypertension associated with benfluorex exposure , 2012, European Respiratory Journal.

[150]  J. Yorke,et al.  The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study , 2012, BMJ Open.

[151]  R. Dweik,et al.  Portopulmonary hypertension: a report from the US-based REVEAL Registry. , 2012, Chest.

[152]  S. Keshavjee,et al.  Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. , 2012, The Journal of thoracic and cardiovascular surgery.

[153]  L. Farkas,et al.  Severe pulmonary hypertension: The role of metabolic and endocrine disorders , 2012, Pulmonary circulation.

[154]  R. Steinhorn,et al.  Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. , 2012, Clinics in perinatology.

[155]  M. Madani,et al.  State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management , 2012, European Respiratory Review.

[156]  A. Torbicki,et al.  Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension , 2012, European Respiratory Journal.

[157]  J. Barberà,et al.  Survival in pulmonary hypertension in Spain: insights from the Spanish registry , 2012, European Respiratory Journal.

[158]  G. Raskob,et al.  Clinical features of paediatric pulmonary hypertension: a registry study , 2012, The Lancet.

[159]  R. Speich,et al.  Safety and efficacy of exercise training in various forms of pulmonary hypertension , 2012, European Respiratory Journal.

[160]  M. Humbert,et al.  Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[161]  Z. Jing,et al.  Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. , 2012, Chest.

[162]  M. Humbert,et al.  Pregnancy outcomes in pulmonary arterial hypertension in the modern management era , 2012, European Respiratory Journal.

[163]  V. Roger,et al.  Pulmonary pressures and death in heart failure: a community study. , 2012, Journal of the American College of Cardiology.

[164]  R. Barst,et al.  A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension , 2012, Circulation.

[165]  R. Barst,et al.  Survival in Childhood Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management , 2011, Circulation.

[166]  D. Ivy,et al.  Initial Experience With Tadalafil in Pediatric Pulmonary Arterial Hypertension , 2011, Pediatric Cardiology.

[167]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[168]  D. Badesch,et al.  ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. , 2009, Cardiovascular therapeutics.

[169]  A. Branzi,et al.  Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger’s Syndrome , 2012, Drugs.

[170]  H. Shimokawa,et al.  Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[171]  H. Marshall,et al.  Black blood MRI has diagnostic and prognostic value in the assessment of patients with pulmonary hypertension , 2012, European Radiology.

[172]  S. Ley,et al.  Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH) , 2012, European Radiology.

[173]  Shengshou Hu,et al.  Combination Therapy in Pulmonary Arterial Hypertension: A Meta-Analysis , 2011, Cardiology.

[174]  V. Russo,et al.  Extensive right pulmonary artery dissection in a young patient with chronic pulmonary hypertension , 2011, Heart.

[175]  Nico Westerhof,et al.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[176]  W. Haefeli,et al.  Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. , 2011, International journal of cardiology.

[177]  J. Granton,et al.  Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. , 2011, American journal of respiratory and critical care medicine.

[178]  A. Wells,et al.  Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. , 2011, Arthritis and rheumatism.

[179]  M. Humbert,et al.  Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. , 2011, Arthritis and rheumatism.

[180]  A. Klein,et al.  Extracorporeal membrane oxygenation as a bridge to pulmonary endarterectomy. , 2011, The Annals of thoracic surgery.

[181]  J. Barberà,et al.  Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results From an International Prospective Registry , 2011, Circulation.

[182]  M. de Pauw,et al.  Iron deficiency is associated with adverse outcome in Eisenmenger patients. , 2011, European heart journal.

[183]  T. Delhaas,et al.  Pediatric Pulmonary Hypertension in the Netherlands: Epidemiology and Characterization During the Period 1991 to 2005 , 2011, Circulation.

[184]  L. Sharples,et al.  Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial , 2011, The Lancet.

[185]  S. Keshavjee,et al.  Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[186]  T. Welte,et al.  The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension , 2011, European Respiratory Journal.

[187]  M. Humbert,et al.  Ventilation/perfusion lung scan in pulmonary veno-occlusive disease , 2011, European Respiratory Journal.

[188]  R. Ewert,et al.  Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. , 2011, Zeitschrift fur Gastroenterologie.

[189]  V. Salemi,et al.  Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease , 2011, European Respiratory Journal.

[190]  J. Wharton,et al.  Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. , 2011, Journal of the American College of Cardiology.

[191]  L. Savale,et al.  A hemodynamic study of pulmonary hypertension in sickle cell disease. , 2011, The New England journal of medicine.

[192]  Z. Jing,et al.  Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[193]  J. Grapsa,et al.  Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. , 2011, International journal of cardiology.

[194]  P. Pellikka,et al.  Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. , 2011, Chest.

[195]  H. Haller,et al.  Osteopontin in patients with idiopathic pulmonary hypertension. , 2011, Chest.

[196]  E. Rosenzweig,et al.  Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. , 2011, The American journal of cardiology.

[197]  Sanjiv J. Shah,et al.  Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction , 2011, Circulation. Heart failure.

[198]  D. Celermajer,et al.  Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. , 2011, The Journal of pediatrics.

[199]  S. Harikrishnan,et al.  A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011 , 2011, Pulmonary circulation.

[200]  D. Ivy,et al.  Pulmonary arterial hypertension: a comparison between children and adults , 2011, European Respiratory Journal.

[201]  A. Torbicki,et al.  Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension. , 2011, Chest.

[202]  M. Madani,et al.  Chronic thromboembolic pulmonary hypertension in pediatric patients. , 2011, The Journal of thoracic and cardiovascular surgery.

[203]  W. Klepetko,et al.  Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. , 2011, The Journal of thoracic and cardiovascular surgery.

[204]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[205]  S. Rosenkranz,et al.  Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension , 2011, Respiration.

[206]  R. Naeije,et al.  Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. , 2011, British journal of clinical pharmacology.

[207]  Rami Dhillon The management of neonatal pulmonary hypertension , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[208]  M. Humbert,et al.  Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? , 2011, Presse medicale.

[209]  I. Schulze-Neick,et al.  Issues related to the management and therapy of paediatric pulmonary hypertension , 2010, European Respiratory Review.

[210]  G. Maurer,et al.  Imaging in pulmonary hypertension. , 2010, JACC. Cardiovascular imaging.

[211]  J. Cracowski,et al.  Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies , 2010, The Journal of Rheumatology.

[212]  S. Ghio,et al.  Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis , 2010, Heart.

[213]  S. Ghio,et al.  Comparison of Brain Natriuretic Peptide (BNP) and NT-proBNP in Screening for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis , 2010, The Journal of Rheumatology.

[214]  Seung‐Jung Park,et al.  Left main coronary artery compression from pulmonary artery enlargement due to pulmonary hypertension: A contemporary review and argument for percutaneous revascularization , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[215]  N. Westerhof,et al.  Iron deficiency is common in idiopathic pulmonary arterial hypertension , 2010, European Respiratory Journal.

[216]  S. Brett,et al.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review , 2010, Critical care.

[217]  Takahiro Shiota,et al.  Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. , 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[218]  T. Welte,et al.  Extracorporeal Membrane Oxygenation in Nonintubated Patients as Bridge to Lung Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[219]  A. Chapelier,et al.  Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[220]  M. Hoeper,et al.  Circulating angiopoietins in idiopathic pulmonary arterial hypertension. , 2010, European heart journal.

[221]  R. Nishimura,et al.  Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction , 2010, Circulation. Heart failure.

[222]  Qi Fu,et al.  Characterization of Static and Dynamic Left Ventricular Diastolic Function in Patients With Heart Failure With a Preserved Ejection Fraction , 2010, Circulation. Heart failure.

[223]  H. Collard,et al.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.

[224]  H. Heinzl,et al.  A noninvasive algorithm to exclude pre-capillary pulmonary hypertension , 2010, European Respiratory Journal.

[225]  M. Humbert,et al.  Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. , 2010, European heart journal.

[226]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[227]  M. Humbert,et al.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[228]  A. Manes,et al.  Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses , 2010, European heart journal.

[229]  Horst Olschewski,et al.  Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.

[230]  K. Iversen,et al.  Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. , 2010, European heart journal.

[231]  M. Humbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[232]  I. Schulze-Neick,et al.  Childhood idiopathic pulmonary arterial hypertension: a national cohort study , 2010, Heart.

[233]  R. Arena,et al.  Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[234]  L. Shapiro,et al.  Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[235]  J. Barberà,et al.  Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. , 2010, American journal of respiratory and critical care medicine.

[236]  M. Loebe,et al.  Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[237]  M. Humbert,et al.  Pulmonary hypertension in patients with chronic myeloproliferative disorders , 2010, European Respiratory Journal.

[238]  M. Humbert,et al.  HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era , 2010, AIDS.

[239]  H. Tan,et al.  Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. , 2010, The Journal of thoracic and cardiovascular surgery.

[240]  Sanjiv J. Shah,et al.  Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation , 2009, European Respiratory Journal.

[241]  R. Barst,et al.  Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study , 2009, British journal of clinical pharmacology.

[242]  M. Humbert,et al.  Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension , 2009, European Respiratory Journal.

[243]  A. Borczuk,et al.  Sarcoidosis-Associated Fibrosing Mediastinitis with Resultant Pulmonary Hypertension: A Case Report and Review of the Literature , 2009, Respiration.

[244]  N. Westerhof,et al.  Effects of exercise training in patients with idiopathic pulmonary arterial hypertension , 2009, European Respiratory Journal.

[245]  J. Vachiéry,et al.  Screening for pulmonary arterial hypertension in systemic sclerosis , 2009, European Respiratory Review.

[246]  M. Rubenfire,et al.  Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need. , 2009, Chest.

[247]  M. Humbert,et al.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome , 2009, European Respiratory Journal.

[248]  S. Halpern,et al.  Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. , 2009, Chest.

[249]  J. Newman,et al.  Association of the metabolic syndrome with pulmonary venous hypertension. , 2009, Chest.

[250]  H. Palevsky,et al.  Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. , 2009, Mayo Clinic proceedings.

[251]  M. Galanski,et al.  Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. , 2009, European journal of radiology.

[252]  M. Maitland,et al.  Inflammation, growth factors, and pulmonary vascular remodeling. , 2009, Journal of the American College of Cardiology.

[253]  Horst Olschewski,et al.  Diagnosis and assessment of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[254]  N. Weissmann,et al.  Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[255]  P. Corris,et al.  Interventional and surgical modalities of treatment in pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[256]  W. Chung,et al.  [Genetics and genomics of pulmonary arterial hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[257]  M. Humbert,et al.  Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease , 2009, European Respiratory Journal.

[258]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[259]  J. Butler,et al.  Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. , 2009, American heart journal.

[260]  Z. Jing,et al.  Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension , 2009, European Respiratory Journal.

[261]  M. D. de Vera,et al.  Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end‐stage liver disease , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[262]  Patrick W O'Leary,et al.  Measurement, interpretation and use of hemodynamic parameters , 2009, Cardiology in the Young.

[263]  H. Tighiouart,et al.  Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. , 2009, American journal of respiratory and critical care medicine.

[264]  T. Nawrot,et al.  C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[265]  M. Corretti,et al.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. , 2009, American journal of respiratory and critical care medicine.

[266]  T. Welte,et al.  Bridge to Thoracic Organ Transplantation in Patients with Pulmonary Arterial Hypertension Using a Pumpless Lung Assist Device , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[267]  A Berghold,et al.  Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review , 2009, European Respiratory Journal.

[268]  M. Beghetti,et al.  Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[269]  M. Humbert,et al.  Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension: Results of a Multicenter European Analysis of Pulmonary Artery Pressure Response to Exercise and Hypoxia , 2009, Circulation.

[270]  P. Corris,et al.  Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. , 2009, American journal of respiratory and critical care medicine.

[271]  M. Humbert,et al.  Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study , 2008, Rheumatology.

[272]  A. Branzi,et al.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.

[273]  D. Badesch,et al.  Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. , 2006, Chest.

[274]  A. Torbicki,et al.  Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. , 2008, Journal of the American College of Cardiology.

[275]  G. Dadlani,et al.  Echocardiography in tetralogy of Fallot , 2008, Cardiology in the Young.

[276]  R. Wiesner,et al.  Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment Subgroups , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[277]  S. Stavropoulos,et al.  Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations. , 2008, Journal of vascular and interventional radiology : JVIR.

[278]  T. Fleming,et al.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension (Annals of Internal Medicine (2008) 149 (521-530)) , 2008 .

[279]  T. Fleming,et al.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.

[280]  M. Zenati,et al.  Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. , 2008, The Annals of thoracic surgery.

[281]  A. Vuylsteke,et al.  Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomy. , 2008, The Annals of thoracic surgery.

[282]  H. Palevsky,et al.  Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. , 2008, Respiratory medicine.

[283]  M. Humbert,et al.  Portopulmonary hypertension: survival and prognostic factors. , 2008, American journal of respiratory and critical care medicine.

[284]  F. Laenger,et al.  Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[285]  M. Tamm,et al.  A randomised, controlled trial of bosentan in severe COPD , 2008, European Respiratory Journal.

[286]  S. Nathan,et al.  Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. , 2008, Respiratory medicine.

[287]  Ashish S Shah,et al.  Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. , 2008, The Annals of thoracic surgery.

[288]  P. Thomas,et al.  Biomarkers in pulmonary hypertension , 2008, European Respiratory Journal.

[289]  M. Humbert,et al.  Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[290]  J. Trotter,et al.  Clinical risk factors for portopulmonary hypertension , 2008, Hepatology.

[291]  R. Benza,et al.  Guidelines for the prevention of central venous catheter‐related blood stream infections with prostanoid therapy for pulmonary arterial hypertension , 2008, International journal of clinical practice. Supplement.

[292]  M. Humbert,et al.  Pulmonary Veno-Occlusive Disease: Clinical, Functional, Radiologic, and Hemodynamic Characteristics and Outcome of 24 Cases Confirmed by Histology , 2008, Medicine.

[293]  M. Gatzoulis,et al.  Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. , 2008, International journal of cardiology.

[294]  G. Simonneau,et al.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.

[295]  B. Wiens,et al.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[296]  M. Heneghan,et al.  Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[297]  M. Manns,et al.  Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases , 2008, Transplantation.

[298]  G. MacGowan,et al.  Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland , 2008, Heart.

[299]  M. Gómez,et al.  Estándares asistenciales en hipertensión pulmonar , 2008 .

[300]  I. Schulze-Neick,et al.  Classifying pulmonary hypertension in the setting of the congenitally malformed heart – cleaning up a dog’s dinner , 2008, Cardiology in the Young.

[301]  R. Berger,et al.  Pulmonary arterial hypertension in congenital cardiac disease – the need for refinement of the Evian-Venice classification , 2008, Cardiology in the Young.

[302]  M. Humbert,et al.  Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. , 2008, Arthritis and rheumatism.

[303]  R. Barst,et al.  Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. , 2008, Journal of the American College of Cardiology.

[304]  G. Baumann,et al.  Long-term follow-up of a fenestrated Amplatzer atrial septal occluder in pulmonary arterial hypertension. , 2007, Chest.

[305]  Y. Allanore,et al.  Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials , 2007, Annals of the rheumatic diseases.

[306]  M. Mitchell,et al.  Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects , 2006, Journal of clinical pharmacology.

[307]  D. Borderie,et al.  High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. , 2008, Arthritis and rheumatism.

[308]  G. Simonneau,et al.  Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. , 2008, American journal of respiratory and critical care medicine.

[309]  J. Barberà,et al.  Standards of care in pulmonary hypertension. , 2008, Revista espanola de cardiologia.

[310]  T. Welte,et al.  Experience with inhaled iloprost and bosentan in portopulmonary hypertension , 2007, European Respiratory Journal.

[311]  R. Naeije,et al.  Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? , 2007, European Respiratory Journal.

[312]  W. Seeger,et al.  Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension , 2007, European Respiratory Journal.

[313]  P. Postmus,et al.  Cardiopulmonary Exercise Test Characteristics in Patients with Chronic Obstructive Pulmonary Disease and Associated Pulmonary Hypertension , 2007, Respiration.

[314]  F. Haddad,et al.  Management strategies for patients with pulmonary hypertension in the intensive care unit* , 2007, Critical care medicine.

[315]  M. Rubens,et al.  Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. , 2007, Journal of the American College of Cardiology.

[316]  M. Humbert,et al.  Results of European post-marketing surveillance of bosentan in pulmonary hypertension , 2007, European Respiratory Journal.

[317]  J. McMurray,et al.  An epidemiological study of pulmonary arterial hypertension , 2007, European Respiratory Journal.

[318]  A. Lammers,et al.  Epoprostenol treatment in children with severe pulmonary hypertension , 2006, Heart.

[319]  P. Engelfriet,et al.  Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease , 2006, Heart.

[320]  T. Welte,et al.  Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension , 2007, European Respiratory Journal.

[321]  G. Klintmalm,et al.  The Impact of Treatment of Portopulmonary Hypertension on Survival Following Liver Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[322]  P. Gishen,et al.  Ventilation–Perfusion Scintigraphy Is More Sensitive than Multidetector CTPA in Detecting Chronic Thromboembolic Pulmonary Disease as a Treatable Cause of Pulmonary Hypertension , 2007, Journal of Nuclear Medicine.

[323]  J. Bronzwaer,et al.  Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. , 2007, European heart journal.

[324]  Grzegorz Opolski,et al.  Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. , 2007, Chest.

[325]  M. Humbert,et al.  Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[326]  W. Klepetko,et al.  Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension , 2007, Journal of thrombosis and haemostasis : JTH.

[327]  R. Oudiz Pulmonary hypertension associated with left-sided heart disease. , 2007, Clinics in chest medicine.

[328]  G. Diller,et al.  Pulmonary Vascular Disease in Adults With Congenital Heart Disease , 2007, Circulation.

[329]  B. Hartmann,et al.  N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. , 2007, Chest.

[330]  M. Humbert,et al.  Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension , 2007, Journal of cardiovascular pharmacology.

[331]  K. Kerr,et al.  Chronic thromboembolic pulmonary hypertension. , 2001, Clinics in chest medicine.

[332]  M. Hoeper,et al.  Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. , 2007, American heart journal.

[333]  Z. Jing,et al.  Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. , 2006, Journal of the American College of Cardiology.

[334]  P. Thistlethwaite,et al.  Venovenous extracorporeal life support after pulmonary endarterectomy: indications, techniques, and outcomes. , 2006, The Annals of thoracic surgery.

[335]  R. Wiesner,et al.  Portopulmonary hypertension: Results from a 10‐year screening algorithm , 2006, Hepatology.

[336]  R. Barst,et al.  Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[337]  T. Abraham,et al.  Tricuspid annular displacement predicts survival in pulmonary hypertension. , 2006, American journal of respiratory and critical care medicine.

[338]  M. Gupta,et al.  Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome: A Preliminary Observational Study , 2006, Circulation.

[339]  F. Herth,et al.  Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension , 2006, Circulation.

[340]  M. Hoeper,et al.  Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension , 2006, European Respiratory Journal.

[341]  R. Speich,et al.  Measurement of quality of life in pulmonary hypertension and its significance , 2006, European Respiratory Journal.

[342]  Nazzareno Galiè,et al.  Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. , 2006, Proceedings of the American Thoracic Society.

[343]  W. Klepetko,et al.  Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. , 2006, Proceedings of the American Thoracic Society.

[344]  J. Krishnan,et al.  Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. , 2006, Arthritis and rheumatism.

[345]  W. Seeger,et al.  Sildenafil treatment for portopulmonary hypertension , 2006, European Respiratory Journal.

[346]  Marshall I Hertz,et al.  Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[347]  G. Barbarini,et al.  Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension , 2006, Heart.

[348]  M. Gatzoulis,et al.  Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. , 2006, Journal of the American College of Cardiology.

[349]  M. Gatzoulis,et al.  Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study , 2006, Circulation.

[350]  A. Nicholson,et al.  Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis: A Clinicopathologic Study of 35 Cases , 2006, The American journal of surgical pathology.

[351]  N. Rothfield,et al.  Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. , 2006, Chest.

[352]  M. Humbert,et al.  The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study , 2006, European Respiratory Journal.

[353]  C. Denton,et al.  Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.

[354]  A. Torbicki,et al.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.

[355]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[356]  N. Panay,et al.  Pregnancy and contraception in heart disease and pulmonary arterial hypertension , 2006, Journal of Family Planning and Reproductive Health Care.

[357]  M. Peberdy,et al.  Prognostic value of heart rate recovery in patients with heart failure. , 2006, American heart journal.

[358]  S. Malhotra,et al.  A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. , 2006, American heart journal.

[359]  S. Nathan,et al.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. , 2006, Chest.

[360]  R. Benza,et al.  Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. , 2006, Chest.

[361]  M. Humbert,et al.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. , 2006, European heart journal.

[362]  M. Humbert,et al.  Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension , 2006, European Respiratory Journal.

[363]  M. Humbert,et al.  Occult alveolar haemorrhage in pulmonary veno-occlusive disease , 2006, European Respiratory Journal.

[364]  J. Loscalzo,et al.  Pulmonary arterial hypertension. , 2004, Annals of medicine.

[365]  M. Humbert,et al.  Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. , 2006, Gastroenterology.

[366]  D. Meads,et al.  The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary Hypertension , 2006, Quality of Life Research.

[367]  M. Humbert,et al.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.

[368]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[369]  G. Derrick,et al.  Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension , 2005, Heart.

[370]  M. Kramer,et al.  Pregnancy Outcome in Patients With Pulmonary Arterial Hypertension Receiving Prostacyclin Therapy , 2005, Obstetrics and gynecology.

[371]  T. Welte,et al.  Goal-oriented treatment and combination therapy for pulmonary arterial hypertension , 2005, European Respiratory Journal.

[372]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[373]  F. López-Ríos,et al.  Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure , 2005, European journal of heart failure.

[374]  R. Barst,et al.  von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. , 2005, Chest.

[375]  P. Brillet,et al.  Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity , 2005, European Respiratory Journal.

[376]  Steven H Abman,et al.  Effects of long-term bosentan in children with pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[377]  P. Poole‐Wilson,et al.  Exercise Intolerance in Adult Congenital Heart Disease: Comparative Severity, Correlates, and Prognostic Implication , 2005, Circulation.

[378]  D. Badesch,et al.  Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[379]  N. Morrell,et al.  Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease , 2005, Respiratory research.

[380]  M. Humbert,et al.  Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol , 2005, Thorax.

[381]  A. Chaouat,et al.  Severe pulmonary hypertension and chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[382]  A. Boobis,et al.  Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. , 2005, British journal of clinical pharmacology.

[383]  J. Wharton,et al.  Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.

[384]  D. Fliser,et al.  Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[385]  W. Seeger,et al.  Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[386]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[387]  D. Benhamou,et al.  Severe Pulmonary Hypertension during Pregnancy: Mode of Delivery and Anesthetic Management of 15 Consecutive Cases , 2005, Anesthesiology.

[388]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[389]  H. Mal,et al.  Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. , 2005, Chest.

[390]  M. de la Morena,et al.  Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience. , 2005, The Journal of thoracic and cardiovascular surgery.

[391]  R. Barst,et al.  Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[392]  W. Hopkins The remarkable right ventricle of patients with Eisenmenger syndrome , 2005, Coronary artery disease.

[393]  Thomas R Fleming,et al.  Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.

[394]  E. Fiumana,et al.  Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells , 2005, Basic Research in Cardiology.

[395]  M. Humbert,et al.  Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[396]  B. Löwe,et al.  Anxiety and Depression in Patients With Pulmonary Hypertension , 2004, Psychosomatic medicine.

[397]  W. Seeger,et al.  Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. , 2004, Journal of the American College of Cardiology.

[398]  M. Humbert,et al.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.

[399]  M. Humbert,et al.  Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. , 2004, AJR. American journal of roentgenology.

[400]  A. Torbicki,et al.  Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[401]  M. Humbert,et al.  Pathologic assessment of vasculopathies in pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[402]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[403]  Paolo Prandoni,et al.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[404]  C. Strassburg,et al.  Portopulmonary hypertension and hepatopulmonary syndrome , 2004, The Lancet.

[405]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[406]  M. Gladwin,et al.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[407]  A. Branzi,et al.  The endothelin system in pulmonary arterial hypertension. , 2004, Cardiovascular research.

[408]  D. Tsikas,et al.  Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans , 2004, Circulation.

[409]  C. Denton,et al.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.

[410]  E. Fadel,et al.  Polymorphism of the Serotonin Transporter Gene and Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease , 2003, Circulation.

[411]  A. Torbicki,et al.  Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension , 2003, Circulation.

[412]  K. Wasserman,et al.  Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[413]  M. Humbert,et al.  Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.

[414]  H. Kauczor,et al.  Value of contrast-enhanced MR angiography and helical CT angiography in chronic thromboembolic pulmonary hypertension , 2003, European Radiology.

[415]  R. Barst,et al.  Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension , 2003, Clinical pharmacology and therapeutics.

[416]  R. Naeije Hepatopulmonary syndrome and portopulmonary hypertension. , 2003, Swiss medical weekly.

[417]  J. E. Hansen,et al.  Pulmonary function in primary pulmonary hypertension. , 2003, Journal of the American College of Cardiology.

[418]  M. Sutton,et al.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. , 2003, American journal of respiratory and critical care medicine.

[419]  T. Medsger,et al.  Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. , 2003, Arthritis and rheumatism.

[420]  A. Cohen-Solal,et al.  Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study , 2003, Hepatology.

[421]  R. Hetzer,et al.  Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. , 2003, European heart journal.

[422]  A. Branzi,et al.  Prostanoids for Pulmonary Arterial Hypertension , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[423]  R. Favaloro,et al.  Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[424]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[425]  T. Williams,et al.  Treatment of Primary Pulmonary Hypertension , 2002 .

[426]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[427]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[428]  R. Hetzer,et al.  Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing , 2002, Circulation.

[429]  S. Keshavjee,et al.  Heart-lung or lung transplantation for Eisenmenger syndrome. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[430]  M. Humbert,et al.  CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension , 2002 .

[431]  M. Humbert,et al.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[432]  G. Koch,et al.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.

[433]  R. Barst,et al.  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[434]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[435]  M. Humbert,et al.  Chemokine RANTES in severe pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[436]  M. Rubenfire,et al.  Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[437]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[438]  J. Cohn Optimal diuretic therapy for heart failure. , 2001, The American journal of medicine.

[439]  J. Sandoval,et al.  Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. , 2001, American journal of respiratory and critical care medicine.

[440]  R. Ewert,et al.  Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.

[441]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[442]  J. Cigarroa,et al.  Relation of pulmonary arterial diastolic and mean pulmonary arterial wedge pressures in patients with and without pulmonary hypertension. , 2001, The American journal of cardiology.

[443]  M. Humbert,et al.  Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. , 2001, Clinics in chest medicine.

[444]  A. Arroliga,et al.  Nocturnal hypoxemia is common in primary pulmonary hypertension. , 2001, Chest.

[445]  J. E. Hansen,et al.  Exercise Pathophysiology in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[446]  A. Chaouat,et al.  "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. , 2001, American journal of respiratory and critical care medicine.

[447]  M. Rubenfire,et al.  Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. , 2001, The European respiratory journal.

[448]  N. Wald The definition of screening , 2001, Journal of medical screening.

[449]  K. Bremme,et al.  Cesarean section under epidural ropivacaine 0.75% in a parturient with severe pulmonary hypertension , 2001, Acta anaesthesiologica Scandinavica.

[450]  J. Feinstein,et al.  Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension , 2001, Circulation.

[451]  L. Tavazzi,et al.  Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. , 2001, Journal of the American College of Cardiology.

[452]  J. Mandel,et al.  Pulmonary veno-occlusive disease. , 2000, American journal of respiratory and critical care medicine.

[453]  W. Colucci,et al.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. , 2000, Circulation.

[454]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[455]  R. Wiesner,et al.  Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[456]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[457]  W. Seeger,et al.  A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. , 2000, Journal of the American College of Cardiology.

[458]  R. Wiesner,et al.  Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension , 1999, Hepatology.

[459]  M. Uematsu,et al.  Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[460]  J. Hohlfeld,et al.  Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[461]  Thomas Albrecht,et al.  Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent , 1999, The Lancet.

[462]  R. Barst,et al.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.

[463]  G. Maislin,et al.  Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[464]  M. Hoeper,et al.  Plasma coagulation profiles in patients with severe primary pulmonary hypertension. , 1998, The European respiratory journal.

[465]  P. Presbitero,et al.  Eisenmenger syndrome. Factors relating to deterioration and death. , 1998, European heart journal.

[466]  S. Rich,et al.  The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. , 1998, Chest.

[467]  L. Sharples,et al.  Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension , 1998, Heart.

[468]  J. Sandoval,et al.  Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. , 1998, Journal of the American College of Cardiology.

[469]  R. Kuzo,et al.  Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. , 1998, Chest.

[470]  M. Humbert,et al.  Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. , 1998, American journal of respiratory and critical care medicine.

[471]  C. Howell,et al.  Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. , 1998, Transplantation.

[472]  S. Lévy,et al.  Long-term effects of cicletanine on secondary pulmonary hypertension. , 1996, Journal of cardiovascular pharmacology.

[473]  S. Swensen,et al.  Mosaic pattern of lung attenuation on CT scans: frequency among patients with pulmonary artery hypertension of different causes. , 1997, AJR. American journal of roentgenology.

[474]  C. Howell,et al.  Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. , 1997, Transplantation.

[475]  J. Murray,et al.  Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger's physiology. , 1996, Journal of clinical anesthesia.

[476]  R. Wiesner,et al.  Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. , 1996, Mayo Clinic proceedings.

[477]  J. Barberà,et al.  Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease , 1996, The Lancet.

[478]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[479]  E. Trulock,et al.  Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[480]  C. Benjamin,et al.  Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. , 1995, Molecular pharmacology.

[481]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[482]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[483]  A. Chaouat,et al.  Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. , 1995, Chest.

[484]  A. Denjean,et al.  Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. , 1995, American journal of respiratory and critical care medicine.

[485]  A. Branzi,et al.  Role of pharmacologic tests in the treatment of primary pulmonary hypertension. , 1995, The American journal of cardiology.

[486]  S. Rich,et al.  Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. , 1995, Chest.

[487]  K. Huber,et al.  Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. , 1994, American journal of respiratory and critical care medicine.

[488]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[489]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[490]  J. Moller,et al.  Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. , 1991, The American journal of cardiology.

[491]  T. Evans,et al.  Adenosine as a Vasodilator in Primary Pulmonary Hypertension , 1991, Circulation.

[492]  D. Stewart,et al.  Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.

[493]  D. Moodie,et al.  Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. , 1991, Journal of the American College of Cardiology.

[494]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[495]  A. Peacock Pulmonary hypertension due to chronic hypoxia. , 1990, BMJ.

[496]  J. Barberà,et al.  Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. , 1990, Chest.

[497]  J. Rouleau,et al.  Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. , 1988, Annals of internal medicine.

[498]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[499]  W. Mckenna,et al.  Echocardiographic measurement of the normal adult right ventricle , 1986 .

[500]  G. Gregoratos,et al.  Fiberoptic angioscopy: role in the diagnosis of chronic pulmonary arterial obstruction. , 1985, Annals of internal medicine.

[501]  E. Weitzenblum,et al.  Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. , 1985, The American review of respiratory disease.

[502]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[503]  G. Simonneau,et al.  Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. , 1981, The New England journal of medicine.

[504]  M. Gee,et al.  Pulmonary injury and prostaglandin production during endotoxemia in conscious sheep. , 1981, The American journal of physiology.